期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 1, 页码 19-22出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61453
关键词
-
资金
- NCI NIH HHS [P01 CA077839, P01 CA77839] Funding Source: Medline
- NIDDK NIH HHS [R37 DK47297, R37 DK047297, R01 DK 62112, R01 DK062112] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK062112] Funding Source: NIH RePORTER
Epoxyeicosatrienoic acids (EETs) generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain cardiovascular and kidney diseases. Hence, great efforts have been made to develop drugs targeting the EET pathway. Some of these agents are currently under evaluation in clinical trials for treatment of hypertension and diabetes. In this issue of the JCI, Panigrahy et al. evaluate in a systematic way the role of CYP epoxygenases and the metabolites they generate in cancer progression. Their findings, along with previous studies, raise concerns about using these drugs in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据